HIV感染合并肾脏病:KDIGO争议会议结论
KDIGO召集国际专家组,界定HIV感染背景下肾脏病的病理类型、遗传因素作用及抗逆转录病毒治疗的肾脏风险获益,并制定预防管理最佳实践。现有指南多外推自普通人群,未充分纳入HIV相关通路与遗传因素。
要点
- HIV阳性者肾脏病风险增加,包括HIV相关肾病、非塌陷型FSGS、免疫复合物肾病及合并症。
- 抗逆转录病毒治疗和机会性感染均可导致肾损伤,需权衡肾脏风险获益。
- 现有指南多外推自普通人群,未充分整合HIV相关通路与遗传因素。
核心结论
- HIV阳性个体肾脏病风险增加,需专门界定病理、遗传及治疗风险获益。
研究设计与样本
- 国际专家组(肾脏病学、肾脏病理学、感染病学)召开KDIGO争议会议。
主要发现
- HIV相关肾脏病包括HIV相关肾病、非塌陷型FSGS、免疫复合物肾病及合并症。
- 长期抗逆转录病毒治疗或机会性感染可导致肾损伤。
- 现有指南多外推自普通人群,未充分纳入HIV相关通路和遗传因素。
临床怎么用
- 需综合评估HIV阳性者肾脏病风险,权衡抗逆转录病毒治疗的肾脏风险获益。
- 预防和管理应纳入HIV相关通路及遗传因素,而非完全照搬普通人群指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.
引用
- Swanepoel CR, Atta MG, D'Agati VD, et al. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2018. PMID: 29398134. doi:10.1016/j.kint.2017.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。